David Campany

Dr. David Campany

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
DCDavid Campany
David Campany
MLMaria Larrosa-Garcia
Maria Larrosa-Garcia
PLPilar Lalueza-Broto
Pilar Lalueza-Broto
LRLucas Rivera-Sánchez
Lucas Rivera-Sánchez
JEJuan Espinosa-Pereiro
Juan Espinosa-Pereiro
CPCarles Pigrau-Serrallach
Carles Pigrau-Serrallach

2 August 2022 in Transplantation
Verified
Journal Article
Open access
MVMiguel Villamarín
Miguel Villamarín
EMEster Marquez-Algaba
Ester Marquez-Algaba
JEJuliana Esperalba
Juliana Esperalba
MPManel Perelló
Manel Perelló
ILIbai Los-Arcos
Ibai Los-Arcos
OLOscar Len
Oscar Len
Background.: Recently, different therapeutic lines have been tried in the initial stage of the disease of COVID-19, including remdesivir and molnupiravir. There is scarce evidence on the efficacy and safety of molnupiravir in kidney transplant recipients (KTRs). Methods.: ingle-center prospective cohort study‚ all adult KTRs diagnosed with COVID-19 and treated with molnupiravir or remdesivir from January to April 2022 were included. Results.: Nine KTRs with SARS-CoV-2 (Omicron variant) infection and mild symptoms received molnupiravir in an outpatient basis and were compared with a cohort of similar patients treated with remdesivir (n = 7). Three patients in the molnupiravir cohort were in the early posttransplant period and received a basiliximab (n = 2) or antithymocite globulin–based induction (n = 1). One of the patients had been treated with methylprednisolone bolus and antithymocite globulin for an episode of acute rejection in the previous months. They were all vaccinated with mRNA vaccines‚ and all but 1 had serological response. Only one of the patients experienced clinical worsening despite molnupiravir treatment and developed pneumonia requiring hospital admission. None of the patients suffered adverse effects attributed to molnupiravir‚ and no adjustment of tacrolimus dose was needed. None of the patients treated with remdesivir progressed in COVID-19 severity. Conclusions.: Our study suggests that KTRs with SARS-CoV-2 infection under treatment with molnupiravir have a good clinical evolution with a probable lower risk for hospitalization and no adverse effects. At the renal level, molnupiravir was well tolerated, with no evidence of nephrotoxicity secondary to the drug nor interactions with the immunosuppressive therapy.

12 September 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
CKCristina Kirkegaard-Biosca
Cristina Kirkegaard-Biosca
EBEster del Barrio-Tofiño
Ester del Barrio-Tofiño
MVMiguel Villamarín
Miguel Villamarín
NLNieves Larrosa
Nieves Larrosa
DCDavid Campany
David Campany
ILIbai Los-Arcos
Ibai Los-Arcos
VIM-type-producing Gram-negative bacteria (GNB) infections are difficult to treat. This is a retrospective single-center study of 34 patients who received cefiderocol for the treatment of VIM-type-producing GNB infections, including 25 Pseudomonas spp., 7 Enterobacterales, and 5 Achromobacter sp. Primary outcomes were clinical failure (defined as death, lack of clinical improvement, or a switch to another drug) at day 14 and 30-day all-cause mortality. The median age was 59 years (IQR 53.7–73.4), and the median Charlson comorbidity index was 3.5 (IQR 2–5). The main infections were respiratory tract infections (n = 9, 27%) and skin and soft tissue infections (n = 9, 27%). Eight patients exhibited bacteremia. In 9/17 patients with a drainable focus, drainage was performed. The median cefiderocol treatment duration was 13 days (IQR 8–24). Five patients (15%) experienced clinical failure on day 14, and the thirty-day mortality rate was 9/34 (27%); two cases occurred because of an uncontrolled infection source, and one was due to a new infection caused by the same bacteria. The other six deaths were unrelated to the index infection. Five patients experienced microbiological recurrence within three months. Susceptibility testing revealed the development of cefiderocol resistance in 1/7 cases with persistent or recurrent positive cultures. Cefiderocol, even in monotherapy, could be considered for the treatment of VIM-type-producing GNB infections.

27 February 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JBJoaquin Burgos
Joaquin Burgos
ACAdrià Curran
Adrià Curran
JGJorge Garcia
Jorge Garcia
DCDavid Campany
David Campany
VDVicente Descalzo
Vicente Descalzo
VFVicenç Falcó
Vicenç Falcó
Background: Doubts remain about the best treatment for managing premalignant lesions (high-grade squamous intraepithelial lesions [HSIL]) associated with anal cancer. Methods: The TREATAIN trial was an open-label, randomized study conducted at Hospital Vall d’Hebron (Spain). Persons with human immunodeficiency virus and anal HSIL were randomly assigned 1:1:1 to receive treatment with electrocautery, topical cidofovir 1% ointment, or topical sinecatechins 10%. The primary outcome was histological resolution of HSIL. Secondary outcomes included adverse events, participant satisfaction, human papillomavirus clearance, and HSIL recurrence. Results: Between October 2020 and November 2022, 100 participants were enrolled (36 in the electrocautery arm, 28 in the cidofovir arm, and 36 in the sinecatechins arm). Modified intention-to-treat analysis showed a response rate of 69.4% (95% confidence interval [CI]: 54.4%–84.5%) of patients in the electrocautery group, 82.1% (95% CI: 67.9%–96.3%) in the cidofovir group, and 61.1% (95% CI: 45.2%–77%) in the sinecatechins group (P = .189). During the 48-week follow-up period, recurrence was observed in 7 participants (28%) in the electrocautery group, 7 (30.4%) in the cidofovir group, and 8 (36.4%) in the sinecatechins group (log-rank test, P = .811). Side effects were reported by 97.2% of patients in the electrocautery group, 85.7% in the cidofovir group, and 33% in the sinecatechins group (P < .001). Patients were more satisfied with the sinecatechins treatment (mean, 5.6 ± 0.4), followed by electrocautery (mean, 5.1 ± 0.8), while lower satisfaction was reported with cidofovir treatment (mean, 4.77 ± 0.96) (P < .001). Conclusions: No statistically significant difference was observed in efficacy between treatments; in contrast, sinecatechins was the most accepted and well-tolerated treatment. Clinical Trials Registration. EudraCT: 2018-001730-18; ClinicalTrials.gov: NCT04055142.

1 April 2022 in Medicina Clinica
Verified
Journal Article
Closed access
ICIgnacio Cardona-Pascual
Ignacio Cardona-Pascual
DBDavid Berlana
David Berlana
FMFerran Martinez-Valle
Ferran Martinez-Valle
DCDavid Campany
David Campany
JMJosé Bruno Montoro-Ronsano
José Bruno Montoro-Ronsano

26 May 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
DCDavid Campany
David Campany
APAlba Pau-Parra
Alba Pau-Parra
PGPablo González‐Moreno
Pablo González‐Moreno
JVJaume Vima‐Bofarull
Jaume Vima‐Bofarull
DADanae Anguita‐Domingo
Danae Anguita‐Domingo
BMBruno Montoro‐Ronsano
Bruno Montoro‐Ronsano